Walter Nmn Ling
University Of California Los Angeles
Project start date: 2009-02-01
Project end date: 2012-12-31
Sponsored Links Excellgen http://Excellgen.com
SUSTAINED-RELEASE METHYLPHENIDATE FOR MANAGEMENT OF METHAMPHETAMINE USE DISORDERS
Walter Nmn Ling, Professor/chief, Substance Abuse Program
University Of California Los Angeles, Office Of Research Administration, Los Angeles, Ca 90095
Grant 5R01DA025084-02 from National Institute On Drug Abuse
Abstract: This four-year study will evaluate the efficacy of treatment with methylphenidate compared to placebo in the context of behavioral therapy for methamphetamine use disorders (abuse or dependence) in a population of 90 adults seeking treatment at the UCLA ISAP Outpatient Clinical Research Center. The project will employ an experimental design involving ramping from two dosage levels of methylphenidate (MPH; 18mg/day for one week, and 36mg/day for one week) to the hypothesized active dosage (54mg/week for 8 weeks). After satisfying all inclusion/exclusion requirements, participants will be enrolled into the study for an initial two weeks for reinforcement of clinic attendance and collection of urine samples--during the first two-week screening period, only attendance is incentivized, with no contingency on results of thrice-weekly urine tests. The motivational incentives component continues throughout the study, with fixed compensation for attendance during the medication phase, in conjunction with escalating opportunities of increased reward for two or more consecutive drug-free urine samples (post run-in). Equal numbers of subjects will be assigned to either placebo or medication to maintain a balanced design, resulting in 45 subjects per condition. Aims of the study are Aim 1. To evaluate the ability of sustained-release MPH (54mg once daily for 8 weeks) to reduce stimulant abuse and increase retention in the protocol among a sample of adults seeking treatment for MA use disorders. Aim 2. To examine the clinical utility of sustained-release MPH as a pharmacotherapy for methamphetamine use disorders. Aim 3. To assess functioning of participants in terms of psychiatric, cognitive, social, and physical domains. There is a critical need for systematic evaluation of strategies for treating methamphetamine use disorders. Thus, this project addresses NIDA´s goal of developing an effective pharmacotherapy for stimulant use disorders, which constitute a considerable public health problem with severe consequences to social service systems, the criminal justice system, and to millions of individuals and families. The proposed research is of considerable public health significance in that it will provide foundational information on a potential medication-based treatment for methamphetamine dependence, a serious drug problem with extensive impacts. If proven effective, the protocol could be useful in reducing drug-related consequences such as criminal activity, social disruption, and elevated risk of HIV transmission/infection due to increased frequency of unsafe sexual activities while on methamphetamine. A combination of treatment approaches may be most effective, and the proposed project will assess the utility of MPH in combination with proven behavioral therapy
Keywords: (+-)-1-(3-Chlorophenyl)-2-((1, 1-dimethylethyl)amino)-1-propa; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester; 21+ years old; 3, 4-Dihydroxyphenethylamine; 4-(2-Aminoethyl)-1, 2-benzenediol; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo, exo))-; AD/HD; ADHD; AIDS Virus; Abstinence; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Acute; Address; Adherence; Adherence (attribute); Adolescent; Adolescent Youth; Adult; Adverse Experience; Adverse effects; Adverse event; After Care; After-Treatment; Aftercare; Amfebutamone; Amphetamine Dependence; Animal Model; Animal Models and Related Studies; Attention deficit hyperactivity disorder; Attention-Deficit Disorder, Predominantly Hyperactive-Impulsive Type; Back; Beck depression inventory; Behavior Conditioning Therapy; Behavior Modification; Behavior Therapy; Behavior Therapy, Cognitive; Behavior Treatment; Behavior or Life Style Modifications; Behavioral Conditioning Therapy; Behavioral Modification; Behavioral Therapy; Behavioral Treatment; Benzeneethanamine, N, alpha-dimethyl-, (S)-; Brain; Bupropion; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Study; Cocaine; Cognitive; Cognitive Therapy; Collection; Common Rat Strains; Compensation; Conditioning Therapy; Control Groups; Criminal Justice; Crystal Meth; DSM; Data; Deoxyephedrine; Dependence; Dependence, Amphetamine; Depression; Desoxyephedrine; Development; Diagnostic and Statistical Manual; Disease; Disorder; Dopamine; Dorsum; Dose; Drug Evaluation, Preclinical; Drug Interactions; Drug Screening; Drug Therapy; Drug usage; Drugs; ECG; EKG; Electrocardiogram; Electrocardiography; Employment Status; Encephalon; Encephalons; Enrollment; Equilibrium; Equipment and supply inventories; European; Evaluation; Evaluation Studies, Drug, Pre-Clinical; Evaluation Studies, Drug, Preclinical; Exclusion; Experimental Designs; Family; Financial compensation; Frequencies (time pattern); Frequency; Funding; Goals; HIV; HTLV-III; Human; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Human, Adult; Human, General; Hydroxytyramine; Hyperactivity Disorder NOS; Hyperactivity Disorder, Predominantly Hyperactive-Impulsive Type; Hyperkinetic Syndrome; Incentives; Incidence; Individual; Infection; Inventory; Justice, Criminal; LAV-HTLV-III; Life; Life Style Modification; Ligand Binding; Lymphadenopathy-Associated Virus; Mammals, Primates; Mammals, Rats; Man (Taxonomy); Man, Modern; Measures; Medical; Medical Inspection; Medication; Memory; Memory, Immediate; Memory, Short-Term; Memory, Shortterm; Mental Depression; Methamphetamine; Methamphetamine dependence; Methylamphetamine; Methylphenidate; N-Methylamphetamine; NIDA; National Institute of Drug Abuse; Nervous System, Brain; Out-patients; Outpatients; PBO; Participant; Patient Self-Report; Pharmaceutic Preparations; Pharmaceutical Preparations; Pharmacotherapy; Phase; Physical Examination; Placebos; Population; Preclinical Drug Evaluation; Primates; Process; Protocol; Protocols documentation; Protocols, Treatment; Proxy; Psychological reinforcement; Psychotherapy, Cognitive; Public Health; RGM; Ramp; Randomized; Rat; Rattus; Recovery; Regimen; Reinforcement; Reinforcement (Psychology); Research; Rewards; Risk; Role; Running; SCHED; Safety; Sampling; Schedule; Screening procedure; Self-Report; Severities; Sex Behavior; Sexual Activity; Sexual Behavior; Sham Treatment; Short-Term Memory; Social Functioning; Social Service; Social Work; Social work (field); Status, Employment; Stimulus; Supervision; Symptoms; System; System, LOINC Axis 4; Testing; Therapy, Cognition; Transmission; Treatment Effectiveness; Treatment Efficacy; Treatment Protocols; Treatment Regimen; Treatment Schedule; Treatment Side Effects; Urinary System, Urine; Urine; VMAT2 Protein; Virus-HIV; Visual; Work; addiction; adult human (21+); analog; attention deficit hyperactive disorder; balance; balance function; base; behavior intervention; behavioral intervention; buproprion; cocaine use; cognitive behavior intervention; cognitive behavior modification; cognitive behavioral intervention; cognitive behavioral modification; cognitive behavioral therapy; cognitive function; craving; design; designing; disease/disorder; dosage; drug use; drug/agent; enroll; extracellular; improved; incentive; indexing; inducement; juvenile; juvenile human; meetings; methamphetamine abuse; model organism; non-drug; novel; placebo controlled study; placebo controlled trial; pre-clinical; preclinical; prevent; preventing; psychostimulant abuse; public health medicine (field); public health relevance; randomisation; randomization; randomly assigned; screening; screenings; sex activity; sham therapy; side effect; social; social role; stimulant abuse; therapeutic efficacy; therapeutically effective; therapy adverse effect; transmission process; treatment adverse effect; uptake; vesicular monoamine transporter 2; working memory
Project start date: 2009-02-01
Project end date: 2012-12-31
Budget start date: 1-JAN-2010
Budget end date: 31-DEC-2010
PFA/PA: PA-07-333
5R01DA025084-02 (2010): $467090
Grants awarded to Walter Nmn Ling
Sustained-Release Methylphenidate For Management Of Methamphetamine Use Disorders
Walter Nmn Ling, Professor
University Of California Los Angeles
Grant 1R01DA025084-01 from National Institute On Drug Abuse IRG: ZDA1
Abstract: This four-year study will evaluate the efficacy of treatment with methylphenidate compared to placebo in the context of behavioral therapy for methamphetamine use disorders (abuse or dependence) in a population of 90 adults seeking treatment at the UCLA ISAP Outpatient Clinical Research Center. The project will employ an experimental design involving ramping from two dosage levels of methylphenidate (MPH; 18mg/day for one week, and 36mg/day for one week) to the hypothesized active dosage (54mg/week for 8 weeks). After satisfying all inclusion/exclusion requirements, participants will be enrolled into the study for an initial two weeks for reinforcement of clinic attendance and collection of urine samples--during the first two-week screening period, only attendance is incentivized, with no contingency on results of thrice-weekly urine tests. The motivational incentives component continues throughout the study, with fixed compensation for attendance during the medication phase, in conjunction with escalating opportunities of increased reward for two or more consecutive drug-free urine samples (post run-in). Equal numbers of subjects will be assigned to either placebo or medication to maintain a balanced design, resulting in 45 subjects per condition. Aims of the study are Aim 1. To evaluate the ability of sustained-release MPH (54mg once daily for 8 weeks) to reduce stimulant abuse and increase retention in the protocol among a sample of adults seeking treatment for MA use disorders. Aim 2. To examine the clinical utility of sustained-release MPH as a pharmacotherapy for methamphetamine use disorders. Aim 3. To assess functioning of participants in terms of psychiatric, cognitive, social, and physical domains. There is a critical need for systematic evaluation of strategies for treating methamphetamine use disorders. Thus, this project addresses NIDA´s goal of developing an effective pharmacotherapy for stimulant use disorders, which constitute a considerable public health problem with severe consequences to social service systems, the criminal justice system, and to millions of individuals and families. The proposed research is of considerable public health significance in that it will provide foundational information on a potential medication-based treatment for methamphetamine dependence, a serious drug problem with extensive impacts. If proven effective, the protocol could be useful in reducing drug-related consequences such as criminal activity, social disruption, and elevated risk of HIV transmission/infection due to increased frequency of unsafe sexual activities while on methamphetamine. A combination of treatment approaches may be most effective, and the proposed project will assess the utility of MPH in combination with proven behavioral therapy
Project start date: 2009-02-01
Project end date: 2012-12-31
OPTIMIZING OUTCOMES USING SUBOXONE FOR OPIATE DEPENDENCE
Walter Nmn Ling, Professor/chief, Substance Abuse Program
University Of California Los Angeles, Office Of Research Administration, Los Angeles, Ca 90095
Grant 5R01DA020210-05 from National Institute On Drug Abuse
Abstract: The approval of buprenorphine (combined with naloxone as Suboxone(r)) by the FDA enables physicians in the United States to provide pharmacotherapy to opioid-dependent patients in private medical settings. Buprenorphine´s wide acceptance and implementation by physicians has been slower than expected, however, and this may be due in part to the nature and necessity of providing comprehensive treatment for opioid-dependent patients. Lessons learned from methadone maintenance make it clear that simply providing opioid substitution does not address the behavioral components of dependence. While there is no lack of behavioral treatment facilities for substance abuse in the United States, what is lacking is an integrative approach to the treatment of opioid dependence using pharmacotherapy in conjunction with empirically based behavioral treatment strategies. This project will evaluate the added therapeutic effects of three specific behavioral strategies, delivered in the context of a basic medical management (med mgmt) platform approaching what physicians do, in general, when prescribing buprenorphine. Two-hundred forty (240) participants will be randomly assigned after a two week stabilization to one of four groups (1) cognitive behavioral therapy (CBT/med mgmt; n=60) emphasizing relapse prevention, (2) contingency management (CM/med mgmt; n=60) providing incentives for successive opioid-free urine tests, (3) a combined group containing both CBT and CM (CBT+CM/med mgmt; n=60), and (4) med mgmt only (neither CBT nor CM; n=60). Experimental behavioral therapies will be delivered for 16 weeks (to study week 18) in conjunction with Suboxone(r) pharmacotherapy. An additional 16 weeks of treatment using Suboxone(r) (to study week 34) will ensue during which no experimental behavioral therapies are provided. All participants enter a buprenorphine taper and return at study week 52 for long-term follow-up evaluations. Outcomes for the trial include illicit drug use (urine drug samples collected three times per week during the first 18 weeks), drug craving, retention (days in the protocol), psychiatric status (depression, mood), HIV-risk behaviors, and treatment feasibility ratings. Results will be used to recommend strategies to optimize buprenorphine treatment outcomes and promote integration of pharmacotherapy and psychosocial/behavioral treatment strategies for physicians and for behavioral treatment facilities treating opioid-dependent patients
Keywords: 6, 14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1, 1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha, 7alpha(S))-; Active Follow-up; Addiction, Opiate; After Care; After-Treatment; Aftercare; Behavior Conditioning Therapy; Behavior Modification; Behavior Therapy; Behavior Therapy, Cognitive; Behavior Treatment; Behavior or Life Style Modifications; Behavioral; Behavioral Conditioning Therapy; Behavioral Modification; Behavioral Therapy; Behavioral Treatment; Buprenorphine; Cognitive Therapy; Conditioning Therapy; Dependence, Opiate; Depression; Diacetylmorphine; Diamorphine; Doctor of Medicine; Drug Therapy; Drug usage; Drugs; Drugs, Illicit; Effectiveness; Evaluation; Evidence based treatment; Experimental Designs; Gender; Guidelines; Heroin; Illicit Drugs; Incentives; Individual; Intervention; Intervention Strategies; Intervention Studies; Investigators; Life Style Modification; M.D.; Maintenance; Maintenances; Measures; Medical; Medication; Mental Depression; Moods; Morphinan-3, 6-diol, 7, 8-didehydro-4, 5-epoxy-17-methyl- (5alpha, 6alpha)-, diacetate (ester); Narcotics; Opiate Addiction; Opiates; Opioid; Outcome; Outcome Measure; Participant; Patients; Pharmaceutic Preparations; Pharmaceutical Preparations; Pharmacological Treatment; Pharmacotherapy; Physicians; Physicians` Offices; Population; Prevention of relapse; Private Practice; Programs (PT); Programs [Publication Type]; Protocol; Protocols documentation; Psychiatric Social Work; Psychosocial Influences; Psychotherapy, Cognitive; Public Health; Randomized; Recommendation; Research Personnel; Researchers; Risk Behaviors; Risky Behavior; SAMHSA; Sampling; Social Service, Psychiatric; Social Work, Psychiatric; Substance Abuse and Mental Health Services Administration; Substance Abuse and Mental Health Services Administration (U.S.); Testing; Therapeutic Effect; Therapy, Cognition; Time; Treatment outcome; United States; United States Substance Abuse and Mental Health Services Administration; Urinary System, Urine; Urine; Variant; Variation; abused drugs; at risk behavior; base; behavior intervention; behavioral intervention; cognitive behavior intervention; cognitive behavior modification; cognitive behavioral intervention; cognitive behavioral modification; cognitive behavioral therapy; contingency management; craving; disorder later incidence prevention; drug craving; drug of abuse; drug use; drug/agent; drugs abused; drugs of abuse; follow-up; improved; incentive; inducement; interventional strategy; opioid addiction; opioid dependence; prevention of disease recurrence; prevention of disorder recurrence; prevention of later incidences of a disorder; prevention of recurrence; programs; psychosocial; psychosocial service; public health medicine (field); randomisation; randomization; randomly assigned; success; treatment effect; treatment program; treatment strategy
Project start date: 2006-09-01
Project end date: 2011-05-31
Budget start date: 1-JUN-2010
Budget end date: 31-MAY-2011
5R01DA020210-05 (2010): $490347
5R01DA020210-04 (2009): $490818
THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
Walter Nmn Ling
University Of California Los Angeles, Office Of Research Administration, Los Angeles, Ca 90095
Grant 2U10DA013045-11 from National Institute On Drug Abuse
Abstract: Responding to RFA-DA-10-009, this application seeks renewal of the Pacific Region Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) to continue improving the quality and delivery of addiction treatments that can be implemented efficiently by community-based treatment providers (CTPs). The ongoing and future research, training, and dissemination activities of the Pacific Region Node, led by Walter Ling, M.D., will serve the CTN mission "to improve the quality of drug abuse treatment throughout the country, using science as a vehicle." The Node will continue to contribute significantly to the CTN effort by its leadership and participation in innovative concept development, rigorous conduct of research, efficient management, and effective dissemination of CTN products. In the most recent funding period, for example, Node participants developed two protocols and currently lead protocol development of CTN0048, Cocaine Use Reduction with Buprenorphine (CURB). Node personnel will continue to develop and disseminate training materials and manuals for use across the CTN, to plan and host CTN-oriented conferences, and disseminate CTN-based findings through trainings, presentations, publications, and Internet-based methods. The Node´s activities will advance the science and increase broad implementation of research-proven treatments in a collaborative manner with other nodes, CTN CTPs, and other providers and researchers worldwide. This renewal proposes adding two CTPs to the existing five, increasing geographic presence and racial/ethnic inclusion as well as ensuring access to every possible setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate development and testing of new medications and behavioral therapies that can be integrated to achieve better outcomes. Innovation, research pacing, and relevance will be enhanced by increasing interaction with provider groups and with researchers examining potential therapies, exploiting the Node´s existing partnerships while building new collaborations and involving more broad-based settings. Renewal of the Pacific Region Node will strengthen CTN efforts through collaborative work with NIDA, CTN participants, and other stakeholders. To promote use of research-proven addiction treatments, the Pacific Region Node will continue its work to incorporate more broad-based settings for CTN research, resulting in greater inclusion of and service to populations that are not comprehensively served by traditional CTPs. The Node will continue collaboration with the overall CTN to identify and address addiction challenges, public health needs, and research issues
Keywords: 3-Hepta, 6-(dimethylamino)-4, 4-diphenyl-; 6, 14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1, 1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha, 7alpha(S))-; Access to Care; Access to Health Care; Access to Healthcare; Accessibility of health care; Adanon; Address; Agonist; Althose; Availability of Health Services; Behavior Conditioning Therapy; Behavior Modification; Behavior Therapy; Behavior Treatment; Behavior or Life Style Modifications; Behavioral Conditioning Therapy; Behavioral Modification; Behavioral Therapy; Behavioral Treatment; Boots Brand of Naloxone Hydrochloride; Bristol-Myers Squibb Brand of Naloxone Hydrochloride; Budgets; Buprenorphine; Clinical; Clinical Research; Clinical Study; Clinical Trials Network; Collaborations; Communities; Conditioning Therapy; Contracting Opportunities; Contracts; Country; Data; Data Collection; Development; Doctor of Medicine; Dolophine; Drug abuse; Drugs; Endo Brand of Naloxone Hydrochloride; Ensure; Evaluation; Funding; Future; Health Care Providers; Health Personnel; Health Services Accessibility; Healthcare Providers; Healthcare worker; Hepatic; Human Resources; Individual; Internet; Investigators; Lamepro Brand of Naloxone Hydrochloride; Lead; Leadership; Life Style Modification; M.D.; Manpower; Manuals; Measures; Medication; Methadone; Methadose; Methods; Mission; Modality; Monitor; Morphinan-6-one, 4, 5-epoxy-3, 14-dihydroxy-17-(2-propenyl)-, (5alpha)-; NIDA; Naloxone; Narcan; Narcanti; National Institute of Drug Abuse; Network-based; Outcome; PROV; Pacific Northwest; Participant; Patients; Pb element; Performance; Persons; Pharmaceutic Preparations; Pharmaceutical Preparations; Population; Process; Programs (PT); Programs [Publication Type]; Protocol; Protocols documentation; Provider; Public Health; Publications; Randomized; Regulatory Affairs; Replacement Therapy; Research; Research Activity; Research Institute; Research Personnel; Research Resources; Research Training; Researchers; Resources; SCHED; Safety; Schedule; Science; Scientific Publication; Screening procedure; Services; Site; Special Population; Substance abuse problem; Suicide; Technology; Testing; Time; TimeLine; Training; Training Activity; United Drug Brand of Naloxone Hydrochloride; WWW; Work; abuse of drugs; abuse of substances; abuses drugs; access to services; access to treatment; addiction; availability of services; base; behavior intervention; behavioral intervention; cocaine use; community based treatment; conference; cost; drug/agent; fatal attempt; fatal suicide; health care availability; health care personnel; health care service access; health care service availability; health care worker; health provider; health services availability; healthcare access availability; healthcare personnel; healthcare service access; healthcare service availability; heavy metal Pb; heavy metal lead; implementation research; improved; innovate; innovation; innovative; intent to die; medical personnel; meetings; member; named group; personnel; programs; protocol development; public health medicine (field); public health relevance; racial and ethnic; racial/ethnic; randomisation; randomization; randomly assigned; screening; screenings; substance abuse; suicidality; symposium; treatment provider; web; world wide web
Project start date: 1999-09-30
Project end date: 2015-08-31
Budget start date: 1-SEP-2010
Budget end date: 31-AUG-2011
PFA/PA: RFA-DA-10-009
2U10DA013045-11 (2010): $943255
3U10DA013045-11S1 (2010): $256500
3U10DA013045-11S2 (2010): $680000
NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
Walter Nmn Ling, Professor/chief, Substance Abuse Program
University Of California Los Angeles, Office Of Research Administration, Los Angeles, Ca 90095
Grant 3U10DA013045-10S4 from National Institute On Drug Abuse
Abstract: In response to RFA-DA-05-001, this application requests continuation of the Pacific Region Node of the "National Drug Abuse Treatment Clinical Trials Network" (CTN). The research, training, and dissemination activities of the Pacific Region Node will continue to serve the CTN objective "to improve the quality of drug abuse treatment throughout the country, using science as a vehicle." The first five years of the CTN have demonstrated the Pacific Region Node´s ability to significantly contribute to the overall CTN effort in terms of research productivity, innovative concept development, rigorous conduct of research, efficient management and administration, and effective dissemination of results. For example, Node participants developed and implemented the first three CTN protocols, developed training materials, procedures, and manuals adopted for use across the CTN, initiated and hosted several CTN-oriented conferences, and extensively disseminated CTN-based findings through trainings, presentations, publication, and Internet-based methods. The Node´s activities will continue to advance the science and increase practical application of research-proven treatments in a collaborative manner with other nodes, with the CTN community treatment providers (CTPs), and with other providers and researchers around the country. This renewal proposes adding three more CTPs to the existing five, increasing representation to account for greater diversity in setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate identification, development, and testing of new medications and behavioral therapies by increasing interaction with other research efforts involving promising therapies. In addition to participation in the CTN, the Pacific Region Node benefits from association with cutting-edge research on medications for drug abuse emerging from the Node´s UCLA environment; for example, UCLA´s P50-funded Medication Development Unit for Stimulant Abuse (Shoptaw), the UCLA-led Methamphetamine Clinical Trials Group (Rawson), the UCLA Clinical Trials Operations Unit (Ling, Rawson and Shoptaw, Phase I and II trials), and other investigations of promising medications and behavioral therapies for treating drug abusers (Ling, Rawson, Shoptaw, Roll, Newton, Longshore) all provide information useful in developing and testing potential CTN protocols
Keywords: 3-Hepta, 6-(dimethylamino)-4, 4-diphenyl-; 6, 14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1, 1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha, 7alpha(S))-; 6-(Dimethylamino)-4, 4-Diphenyl-3-Heptanol Acetate; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo, exo))-; AIDS Virus; Accounting; Acetylmethadol; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Adanon; Addiction, Opiate; Address; Adopted; Alphacetylmethadol; Althose; Behavior Conditioning Therapy; Behavior Modification; Behavior Therapy; Behavior Treatment; Behavior or Life Style Modifications; Behavioral Conditioning Therapy; Behavioral Modification; Behavioral Therapy; Behavioral Treatment; Benzeneethanamine, N, alpha-dimethyl-, (S)-; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Bp50; Bristol-Myers Squibb Brand of Naltrexone Hydrochloride; Buprenorphine; CD40; CDW40; Clinical Cooperative Groups; Clinical Trial Groups; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Clinical Trials, Unspecified; Cocaine; Collaborations; Communicable Diseases; Communities; Conditioning Therapy; Conduct Clinical Trials; Country; Crystal Meth; Deoxyephedrine; Dependence, Opiate; Desoxyephedrine; Development; Doctor of Medicine; Doctor of Philosophy; Dolophine; Drug abuse; Drug abuser; Drugs; Du Pont Brand of Naltrexone Hydrochloride; Environment; Equilibrium; FDA; Food and Drug Administration; Food and Drug Administration (U.S.); Funding; Future; Goals; HIV; HTLV-III; Health Care Providers; Health Personnel; Healthcare Providers; Healthcare worker; History; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; In element; Indium; Industry; Infectious Disease Pathway; Infectious Diseases; Infectious Diseases and Manifestations; Infectious Disorder; Internet; Investigation; Investigators; LAAM; LAV-HTLV-III; Lamepro Brand of Naltrexone Hydrochloride; Lead; Levamethadyl; Levo-alpha-Acetylmethadol; Levomethadyl Acetate; Life Style Modification; Lymphadenopathy-Associated Virus; M.D.; MGC9013; Manuals; Medication; Methadone; Methadose; Methadyl Acetate; Methamphetamine; Methods; Methylamphetamine; Mission; Misuses drugs; Modality; Morphinan-6-one, 17-(cyclopropylmethyl)-4, 5-epoxy-3, 14-dihydroxy-, (5alpha)-; Movement; Multi-Institutional Clinical Trial; Multi-center clinical study; Multi-center clinical trial; Multi-site clinical study; Multi-site clinical trial; N-LAMM; N-Methylamphetamine; NIDA; NIH; NIH RFA; Nalorex; Naltrexone; National Institute of Drug Abuse; National Institutes of Health; National Institutes of Health (U.S.); Nemexin; Network-based; Operation; Operative Procedures; Operative Surgical Procedures; Opiate Addiction; Orphan Brand of Naltrexone Hydrochloride; Outcome; PROV; Participant; Pb element; Ph.D.; PhD; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase I/II Trial; Play; Policies; Principal Investigator; Problem drug user; Procedures; Productivity; Programs (PT); Programs [Publication Type]; Progress Reports; Protocol; Protocols documentation; Provider; Publications; ReVia; Recording of previous events; Request for Applications; Research; Research Personnel; Research Training; Researchers; Role; Schering-Plough Brand of Naltrexone Hydrochloride; Science; Scientific Publication; Screening procedure; Seminal; Special Population; Structure; Substance abuse problem; Surgical; Surgical Interventions; Surgical Procedure; TNFRSF5; TNFRSF5 gene; Testing; Time; Training; Tumor Necrosis Factor Receptor Superfamily Member 5 Gene; USFDA; United Drug Brand of Naltrexone Hydrochloride; United States Food and Drug Administration; United States National Institutes of Health; Virus-HIV; WWW; Work; abuse of drugs; abuse of substances; abuses drugs; addiction; application in practice; balance; balance function; base; behavior intervention; behavioral intervention; body movement; clinical investigation; community based treatment; community setting; conference; drug/agent; expectation; health care personnel; health care worker; health provider; healthcare personnel; heavy metal Pb; heavy metal lead; improved; innovate; innovation; innovative; medical personnel; methadylacetate; multi center clinical study; multi center clinical trial; multi site clinical study; multi site clinical trial; multi-site trial; named group; opioid addiction; opioid dependence; p50; practical application; programs; psychostimulant abuse; research based treatment; response; screening; screenings; social role; special interest group; stimulant abuse; substance abuse; surgery; symposium; treatment provider; web; working group; world wide web
Project start date: 1999-09-30
Project end date: 2010-08-31
Budget start date: 1-SEP-2009
Budget end date: 31-AUG-2010
PFA/PA: RFA-DA-05-001
3U10DA013045-10S4 (2010): $745343
5U10DA013045-10 (2009): $1250000
5U10DA013045-09 (2008): $1250000
3U10DA013045-09S1 (2008): $1327000
Sponsored Links Excellgen http://Excellgen.com
3U10DA013045-10S3 (2009): $2267457
3U10DA013045-10S2 (2009): $104545
3U10DA013045-10S1 (2009): $99868